The global ankylosing spondylitis market size is expected to reach USD 8.45 billion by 2028 according to a new study by Polaris Market Research. The report “Ankylosing Spondylitis Market Share, Size, Trends, Industry Analysis Report, By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia, Others); By Treatment Type (Painkillers and NSAIDs, DMARDs, Biological Therapies, Steroids, Physical Therapies, Surgery); By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Ankylosing Spondylitis (AS), also known as Bechterew disease is the rare type of arthritis causing stiffness and intense pain in the individual’s spine, starting from lower back sacral bones. AS could also spread to the neck region and damage to other adjoining joints. Ankylosis simply means bone fusion and hard connective tissue and spondylitis means inflammation in the spine and lower part of the vertebrae.
Request for a sample of this research report @ https://www.polarismarketresearch.com/industry-analysis/ankylosing-spondylitis-market/request-for-sample
However, there is no cure for ankylosing spondylitis, but medication and proper exercise workouts can ease pain in the spine. Ankylosing spondylitis is started from an individual’s sacroiliac joints, where the spinal cord connects with the pelvic girdle. It impacts the connecting regions of tendons and ligaments attached to the bones and can even fuse an individual’s vertebrae.
Ankylosing spondylitis could cause inflammation and stiffness throughout the body, in few cases spine becomes weak, likely to be fractured easily, also interrupts the functioning of the cauda equine, group of nerves responsible for an individual’s bowel movements, reflexes, and sexual desires, around 40 percent of the patients suffering from AS are likely to suffer from eye-related problem uveitis, eye inflammation causing blurred vision, and individuals with AS in rare cases have large aorta.
Still, researchers are not being able to figure out what triggers ankylosing spondylitis, but there is a strong narrative that people with ankylosing spondylitis have a gene that codes protein called human leukocyte antigen B27 (HLA-B27). HLAs are the proteins, which help an individual’s immune system to differentiate between its cells and foreign particles, though, according to the Spondylitis Association of America, only 2 percent of the people in the market having HLA-B27 gene are expected to develop ankylosing spondylitis in the future. Men are more likely to suffer from ankylosing spondylitis than women, it starts during adulthood, 80 percent of the cases usually begin before 30, and more than 95 percent, by the age of 45.
Rising prevalence of ankylosing spondylitis with faulty lifestyles coupled with patient awareness and new product approvals driving the market forward. According to the recent population estimates the prevalence rate of ankylosing spondylitis in the U.S. is around 0.2-0.5 percent and based on market data from multiple countries the global incidence rate was stood at 0.4-14 per 100,000 individuals.
Browse for full research summary: https://www.polarismarketresearch.com/industry-analysis/ankylosing-spondylitis-market
Ankylosing spondylitis prevalence increase to about 5 percent for the individual who is HLA B27 positive. Companies such as AbbVie, Inc., Pfizer, Inc., Novartis AG, Amgen, Inc., Johnson & Johnson Services, Inc., Eli Lilly and Company, UCB, Inc., and Merck & Co., Inc. are some of the key players operating in the global ankylosing spondylitis market.
Polaris Market Research has segmented the Ankylosing Spondylitis Market report on the basis of drug, treatment type, and region:
Ankylosing Spondylitis, Drug Outlook (Revenue – USD Million, 2016 – 2028)
- Cosentyx
- Humira
- Simponi
- Remicade
- Enbrel
- Cimzia
- Others
Ankylosing Spondylitis, Treatment Type Outlook (Revenue – USD Million, 2016 – 2028)
- Painkillers and non-steroidal anti-inflammatory drugs (NSAIDs)
- Disease-modifying anti-rheumatic drugs (DMARDs)
- Biological therapies
- Steroids
- Physical therapies
- Surgery
Ankylosing Spondylitis, Regional Outlook (Revenue – USD Million, 2016 – 2027)
- North America
- U.S.
- Canada
- Europe
- France
- Germany
- UK
- Italy
- Spain
- Netherlands
- Austria
- Asia Pacific
- China
- India
- Japan
- Malaysia
- South Korea
- Indonesia
- Central & South America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Avail discount on this report @ https://www.polarismarketresearch.com/industry-analysis/ankylosing-spondylitis-market/request-for-discount-pricing
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. We provide unmatched quality of offerings to our clients present globally. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities.
Contact us-
Polaris Market Research
Phone: 1-646-568-9980
Email: [email protected]
Web: http://www.polarismarketresearch.com
The global ankylosing spondylitis market size is expected to reach USD 8.45 billion by 2028 according to a new study by Polaris Market Research.
The report “Ankylosing Spondylitis Market Share, Size, Trends, Industry Analysis Report, By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia, Others); By Treatment Type (Painkillers and NSAIDs, DMARDs, Biological Therapies, Steroids, Physical Therapies, Surgery); By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Ankylosing spondylitis could cause inflammation and stiffness throughout the body, in few cases spine becomes weak, likely to be fractured easily, also interrupts the functioning of the cauda equine, group of nerves responsible for an individual’s bowel movements, reflexes, and sexual desires, around 40 percent of the patients suffering from AS are likely to suffer from eye-related problem uveitis, eye inflammation causing blurred vision, and individuals with AS in rare cases have large aorta.
Still, researchers are not being able to figure out what triggers ankylosing spondylitis, but there is a strong narrative that people with ankylosing spondylitis have a gene that codes protein called human leukocyte antigen B27 (HLA-B27).
HLAs are the proteins, which help an individual’s immune system to differentiate between its cells and foreign particles, though, according to the Spondylitis Association of America, only 2 percent of the people in the market having HLA-B27 gene are expected to develop ankylosing spondylitis in the future.
Rising prevalence of ankylosing spondylitis with faulty lifestyles coupled with patient awareness and new product approvals driving the market forward.
The global ankylosing spondylitis market size is expected to reach USD 8.45 billion by 2028 according to a new study by Polaris Market Research.
The report “Ankylosing Spondylitis Market Share, Size, Trends, Industry Analysis Report, By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia, Others); By Treatment Type (Painkillers and NSAIDs, DMARDs, Biological Therapies, Steroids, Physical Therapies, Surgery); By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Ankylosing Spondylitis (AS), also known as Bechterew disease is the rare type of arthritis causing stiffness and intense pain in the individual’s spine, starting from lower back sacral bones.
AS could also spread to the neck region and damage to other adjoining joints.
Ankylosing spondylitis could cause inflammation and stiffness throughout the body, in few cases spine becomes weak, likely to be fractured easily, also interrupts the functioning of the cauda equine, group of nerves responsible for an individual’s bowel movements, reflexes, and sexual desires, around 40 percent of the patients suffering from AS are likely to suffer from eye-related problem uveitis, eye inflammation causing blurred vision, and individuals with AS in rare cases have large aorta.
Still, researchers are not being able to figure out what triggers ankylosing spondylitis, but there is a strong narrative that people with ankylosing spondylitis have a gene that codes protein called human leukocyte antigen B27 (HLA-B27).
Prolozone is a safe and effective non-surgical treatment for many kinds of acute and chronic musculoskeletal pain.
If you are suffering from knee pain, back pain, hip pain, or shoulder pain prolozone therapy is an effective treatment to not just ease pain, but to treat the cause of pain.
At NW Integrative Medicine, we offer our patients the best prolozone treatment near Kennewick.
If you are interested to know more about Prolozone therapy, call us at 509 943-2101 for a consultation.
In 2017, the consumer electronics segment dominated the global market, in terms of revenue.
In 2017, Asia-Pacific accounted for the majority share in the global Capacitive Sensors market.Capacitive Sensors Market Is Expected to Reach USD 40 Billion in 2026 The demand for capacitive sensors has increased owing to rising demand for consumer electronics, growing demand for vehicles from emerging economies, and modernization of vehicles.
The rising use of capacitive sensors in consumer devices, and growing demand from healthcare sector has resulted in the capacitive sensors market growth.
The rising adoption of touch screen displays, and connected devices has increased the demand for capacitive sensors across the globe.
The growing implementation of scratch-resistant non-glass surfaces, and miniaturization of sensors further accelerates the adoption of capacitive sensors.
Growing demand from emerging economies, development of smart devices, increasing adoption of IoT, and technological advancements are factors expected to provide numerous growth opportunities in the coming years.
